celgene bms (Celgene)
86
Structured Review
Celgene
celgene bms
Celgene Bms, supplied by Celgene, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/celgene+bms/bms+celgene/pm42310690-483-12-12
Average 86 stars, based on 1 article reviews
Celgene Bms, supplied by Celgene, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/celgene+bms/bms+celgene/pm42310690-483-12-12
Average 86 stars, based on 1 article reviews
celgene bms - by Bioz Stars,
2026-09
86/100 stars
Images
Related Articles
other:Article Title: Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study Article Snippet: E.K.H. received grants or contracts from Czech Ministry of Education—project Cooperatio LF1, research area Neuroscience and the project National Institute for Article Title: Impact of renal function impairment on kappa free light chain index. Article Snippet: Objectives: To investigate whether renal function impacts CSF κ-FLC concentration and/or κ-FLC index.. Methods: Patients with non-inflammatory neurological diseases were eligible. κ-FLC index was calculated as (CSF κ-FLC/ serum κ-FLC)/albumin quotient.. Structural equation modeling (SEM) was used to evaluate the direct influence of GFR on serum κ-FLC concentration and albumin quotient (Qalb), and via these two variables the indirect influence on CSF κ-FLC concentration. Article Title: Personalized therapy in multiple sclerosis: an Italian Delphi consensus. Article Snippet: Maria Pia Amato has received research grants from the National MS Society, Canadian MS Society, Italian Health Ministry, Article Title: Higher disease reactivation risk in women after fingolimod withdrawal. Article Snippet: Chan A received Article Title: The Use of Patient-Reported Outcome Measures in Developmental Age: A Complementary Tool for Pediatric Multiple Sclerosis Prognosis. Article Snippet: Maria Pia Amato has received research grants by the National MS Society, Canadian MS Society, Italian Health Ministry, Article Title: Objective Sleep–Wake Findings in Patients with Post-COVID-19 Syndrome, Fatigue and Excessive Daytime Sleepiness Article Snippet: Andrew Chan received honoraria for Article Title: Risk stratification for disease reactivation after therapy de-escalation/discontinuation in relapsing multiple sclerosis by the VIAADISC score. Article Snippet: Clinical Proteomics:Article Title: Article Snippet: .. 10 Clinical Stage Lead Program: Fibrosis & Anti - TNF Targeting common diseases - facilitates trials and potential sales Clinical trials supported by Prof Sallie Lamb, UK Developing targeted therapies for: • Early Stage Dupuytren’s disease (DD) - patent issued; Phase 2b/3 results expected Q4 2021 (1) • Frozen shoulder - patent issued; clinical trials projected in Q3 2021 • Post operative cognitive decline (POCD) - patent issued, clinical trials projected in Q4 2021 • Liver fibrosis (NASH) - initial laboratory studies done with |